ENA-Modified Tau ASOs for Stable Exon 10 Splicing Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional MOE-modified antisense oligonucleotides (ASOs) are insufficient in tau splicing regulating potency and in vivo stability, requiring high doses for therapeutic effects and potentially causing adverse events, with no effective treatments for tauopathies like frontotemporal dementia (FTD).
Innovation Solution
Development of 2′-O, 4′-C-ethylene-bridged nucleic acid (ENA)-modified ASOs targeting specific regions within exon 10 or intron 10 of tau mRNA precursors, which exhibit superior tau exon 10 skipping and 4R-tau/3R-tau isoform ratio regulation, providing stable and effective treatment for tauopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional MOE-modified ASOs are used for tau splicing regulation, then therapeutic effects can be achieved, but high doses are required which may cause adverse events
Solution Approach 1:
The patent changes the chemical structure parameter of the ASO by replacing MOE modification with ENA (2′-O,4′-C-ethylene-bridged nucleic acid) modification. This structural parameter change results in significantly improved tau splicing regulating potency, allowing therapeutic effects to be achieved at lower doses and thereby reducing adverse events associated with high-dose administration.
Solution Approach 2:
The patent employs a composite chemical structure combining ENA modification with specific nucleotide sequences targeting tau exon 10. This composite approach creates an ASO with enhanced stability and potency, achieving therapeutic effects at reduced doses and minimizing adverse events while maintaining effective tau splicing regulation.
2Reliability
If conventional MOE-modified ASOs are used for tau splicing regulation, then therapeutic effects can be achieved, but in vivo stability is insufficient requiring high doses
Solution Approach 1:
The patent modifies the chemical composition parameter by introducing ENA (2′-O,4′-C-ethylene-bridged nucleic acid) modification to the ASO structure. This parameter change confers superior in vivo stability to the ASO, enabling it to maintain therapeutic activity at lower doses and reducing the need for high-dose administration to achieve sustained therapeutic effects.
3Productivity
If high doses of MOE-modified ASOs are administered to achieve therapeutic effects, then tau splicing can be regulated, but adverse events increase
Solution Approach 1:
The patent changes the chemical structure parameter from MOE to ENA modification, which dramatically improves tau splicing regulating potency. This parameter change allows the ASO to achieve effective tau splicing regulation at lower doses, thereby maintaining productivity while significantly reducing adverse events associated with high-dose administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ENA-modified ASOs achieve sustained tau exon 10 skipping and normalization of the 4R-tau/3R-tau isoform ratio, reducing adverse events and effectively treating tauopathies while allowing for reduced dosing and manufacturing costs.
Implementation Method 1
ASO, which is an artificial nucleic acid, forms Watson-Crick base pairs with RNA in the nucleus, and enables specific regulation of RNA expression
Data Source
AI summary
The present invention provides a tau exon 10 skipping-promoting antisense oligonucleotide containing at least one 2′-O, 4′-C-ethylene-bridged nucleic acid, and a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a region consisting of the nucleotide sequence shown in SEQ ID NO: 44 in exon 10 of a tau mRNA precursor. In addition, the present invention provides a tau exon 10 skipping-suppressing antisense oligonucleotide containing at least one 2′-O, 4′-C-ethylene-bridged nucleic acid, and a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a region consisting of the nucleotide sequence shown in SEQ ID NO: 45 in intron 10 of a tau mRNA precursor.